Trial Profile
Phase I/II study of subcutaneous administration of pegylated-interferon alpha-2a (RO 25-8310) in previously untreated patients with locally advanced or metastatic renal cell carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2010
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2005 New trial record.